{
    "nctId": "NCT01419717",
    "briefTitle": "Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer",
    "officialTitle": "Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 129,
    "primaryOutcomeMeasure": "Number of Participants With Adverse Events",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Subject was previously enrolled in a denosumab phase 3 study and participated in the Open-label Extension portion of that study.\n* Subject or subject's legally acceptable representative has provided informed consent.\n\nExclusion Criteria:\n\n* Subject is of child bearing potential and planning to become pregnant within 7 months after the end of treatment.\n* Subject is of child bearing potential and is not willing to use, in combination with her partner, two highly effective methods of contraception during treatment and for 7 months after the end of treatment.\n* Subject has known sensitivity to any of the products to be administered during dosing.\n* Subject will not be available for protocol required study visits or procedures, to the best of the subject and investigator's knowledge.\n* Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}